Stockreport

Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Vir Biotechnology, Inc.  (VIR) 
PDF – Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial –– Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p. [Read more]